Skip to content
  • Intranet
  • Contact
  • Timeline
  • Project
    • About PROMISE
    • Our ambition
    • Impact
    • Work Packages (WP)
    • Governance
  • Participants
    • Partners
    • Affiliated Partners
    • Advisory Boards
  • RSV
    • What is RSV?
    • RSV Awareness
  • Patients
    • RSV Patient Network
    • Engagement sessions
    • Survey
  • Surveillance
    • Surveillance platform
    • Electronic Fortnightly Bulletin
    • RSVLabNet
    • Study designs
  • Dissemination
    • Factsheet
    • Deliverables
    • Publications
    • Events
    • News
    • Newsletters
  • Project
    • About PROMISE
    • Our ambition
    • Impact
    • Work Packages (WP)
    • Governance
  • Participants
    • Partners
    • Affiliated Partners
    • Advisory Boards
  • RSV
    • What is RSV?
    • RSV Awareness
  • Patients
    • RSV Patient Network
    • Engagement sessions
    • Survey
  • Surveillance
    • Surveillance platform
    • Electronic Fortnightly Bulletin
    • RSVLabNet
    • Study designs
  • Dissemination
    • Factsheet
    • Deliverables
    • Publications
    • Events
    • News
    • Newsletters

GlaxoSmithKline Biologicals, S.A.

Share this page

Previous Next

GlaxoSmithKline Biologicals, S.A.

By albert|2022-03-10T09:44:39+00:00March 4, 2022|Comments Off on GlaxoSmithKline Biologicals, S.A.

Share This Story, Choose Your Platform!

FacebookTwitterRedditLinkedInWhatsAppTelegramTumblrPinterestVkXingEmail

About the Author: albert

Acknowledgement

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 101034339. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

Legal Notice
Privacy Policy
Cookies policy
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences.

© 2023 | IMI-Promise

Close Sliding Bar Area
Tweets by IMI-PROJECT
Page load link
Tweets by IMI-PROJECT
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. Cookie Settings Accept all Reject

Tracking Cookies

Collect information about user navigation through the site in order to know the origin of the visits and other similar data at a statistical level.

Third Party Embeds

Google Maps

Cookies policy

Cookies policy

Privacy policy

Privacy policy
Go to Top